Summary of HR 3631 — VITAL Act of 2025

Official title and purpose (as introduced)

• Bill Number: HR 3631
• Short title: The Vaccines in Trial and Liability Act of 2025, also cited as the VITAL Act of 2025.

Notes:
- The available information confirms only the short title and citation language. The full text detailing the bill’s substantive provisions is not provided here.

Legislative actions to date

• Introduced in the House on May 29, 2025.
• Referred on May 29, 2025 to:
  • Committee on Energy and Commerce
  • Committee on the Judiciary
  • Referral for a period to be determined by the Speaker, in each case for consideration of provisions within that committee’s jurisdiction.
• Sponsor: Mark E. Green (primary)

Sponsorship

• Primary sponsor: Rep. Mark E. Green

What the bill would do (based on available information)

• The only explicitly available content is the bill’s title and citation. No detailed provisions, sections, or operative text have been provided in the current description.
• Therefore, the specific policy changes, regulatory framework, liability standards, or funding mechanisms (if any) cannot be stated from the provided text.

Who/what could be affected (unknown from available text)

• Because substantive provisions are not included, it is not possible to identify specific programs, stakeholders, or statutory regimes that would be directly affected.
• Potential impacts typically associated with a title involving “Vaccines,” “Trial,” and “Liability” could involve researchers, trial participants, manufacturers, and screening/regulatory processes, but actual effects would depend on the enacted text.

Procedural and timeline considerations

• Status: Introduced in the House and referred to two committees (Energy and Commerce; Judiciary).
• Next steps (historically): If reported out of committee, the bill could move to floor consideration in the House, followed by potential action in the Senate. Timelines depend on committee activity and floor scheduling.
• As introduced, there are no committee reports or floor amendments documented in the provided information.

What to watch for in the full text

• The exact provisions governing vaccines in trial settings
• Any liability protections, waivers, or civil liability standards
• Regulatory oversight, funding, or enforcement mechanisms
• Definitions of key terms (e.g., “trial,” “vaccine,” “liability”)
• Interaction with existing federal vaccine or public health laws

If you can share the full text or a summary of the substantive sections, I can provide a detailed, section-by-section analysis and impact assessment.